We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cinvanti

News List

Heron Begins Phase 2 Clinical Study of Cinvanti for COVID-19 americanpharmaceuticalreview
July 27, 2020
Heron Therapeutics announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19).
Heron Announces FDA Approval of sNDA to Expand CINVANTI® Label for IV Push americanpharmaceuticalreview
February 28, 2019
Heron Therapeutics announced the U.S. Food and Drug Administration (FDA) has approved Heron's supplemental New Drug Application (sNDA) for CINVANTI (aprepitant) injectable emulsion...
Heron takes on Merck's Emend with FDA win for antinausea drug Cinvanti fiercepharma
November 13, 2017
Merck’s drug for chemo-induced nausea and vomiting has some new competition.